naptumomab estafenatox

a recombinant fusion protein developed from ABR-214936,6 consisting of a mutated variant of the superantigen (SAg) SEA/E-1207 linked to a fragment antigen binding (Fab) moiety of a monoclonal antibody recognizing the tumor-associated oncofetal trophoblast glycoprotein antigen 5T4

Also Known As:

ABR-217620; Anyara; Anyara TTS CD3; TTS-CD3

Networked: 7 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hedlund, Gunnar: 6 articles (01/2016 - 09/2009)
2.	Forsberg, Göran: 4 articles (02/2014 - 09/2009)
3.	Hawkins, Robert E: 2 articles (01/2016 - 02/2015)
4.	Nordle, Örjan: 2 articles (01/2016 - 02/2015)
5.	Sundstedt, Anette: 2 articles (02/2015 - 01/2013)
6.	Hawkins, Robert: 2 articles (02/2014 - 09/2009)
7.	Bondar, Vladimir: 1 article (01/2016)
8.	Bondarenko, Igor: 1 article (01/2016)
9.	Eisen, Timothy: 1 article (01/2016)
10.	Forsberg, Goran: 1 article (01/2016)

Related Diseases

1.	Renal Cell Carcinoma (Grawitz Tumor) 01/01/2016 - "To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell carcinoma (RCC). " 02/28/2015 - "Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α." 02/01/2014 - "Naptumomab estafenatox has been clinically tested in a range of solid tumors with focus on renal cell carcinoma. " 01/01/2016 - "A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis." 09/01/2009 - "Patients with non-small-cell lung cancer (NSCLC), pancreatic cancer (PC), and renal cell cancer (RCC) received 5 daily boluses of ABR-217620 (3-month cycles) in escalating doses to determine the maximum-tolerated dose (MTD; ABR-217620 dose escalation monotherapy [MONO] study). "
2.	Neoplasms (Cancer) 01/01/2013 - "The T lymphocyte engagement by ABR-217620 is constituted by displaying high affinity binding to the tumor cells (KD approximately 1 nM) and with the mimicry of natural productive immune TCR-pMHC contact using affinities of around 1 µM. " 01/01/2013 - "ABR-217620 selectively triggers TRBV7-9 expressing cytotoxic T lymphocytes to kill 5T4 positive tumor cells. " 06/01/2010 - "Naptumomab estafenatox induces dramatic reduction of established human tumors in Severe Combined Immunodeficient mice grafted with human lymphocytes. " 02/01/2014 - "Naptumomab estafenatox has been clinically tested in a range of solid tumors with focus on renal cell carcinoma. " 06/01/2010 - "Thus, naptumomab estafenatox is a novel optimized tumor-targeted superantigen currently investigated in clinical trials."
3.	Pancreatic Neoplasms (Pancreatic Cancer) 09/01/2009 - "Patients with non-small-cell lung cancer (NSCLC), pancreatic cancer (PC), and renal cell cancer (RCC) received 5 daily boluses of ABR-217620 (3-month cycles) in escalating doses to determine the maximum-tolerated dose (MTD; ABR-217620 dose escalation monotherapy [MONO] study). "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/01/2009 - "Patients with non-small-cell lung cancer (NSCLC), pancreatic cancer (PC), and renal cell cancer (RCC) received 5 daily boluses of ABR-217620 (3-month cycles) in escalating doses to determine the maximum-tolerated dose (MTD; ABR-217620 dose escalation monotherapy [MONO] study). " 09/01/2009 - "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer."
5.	Carcinoma (Carcinomatosis) 02/01/2014 - "Naptumomab estafenatox targets the 5T4 tumor antigen, a 72-kDa oncofetal trophoblast protein expressed on many carcinomas, including renal cell carcinoma. "

Related Drugs and Biologics

1.	Superantigens
2.	naptumomab estafenatox
3.	Biomarkers (Surrogate Marker)
4.	Docetaxel (Taxotere)
5.	Proteins (Proteins, Gene)
6.	T-Cell Antigen Receptors (T-Cell Receptor)
7.	Neoplasm Antigens (Tumor Antigens)
8.	Antigens
9.	Immunotoxins (Immunotoxin)
10.	Monoclonal Antibodies